Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ropeginterferon alfa 2b - AOP Orphan Pharmaceuticals/PharmaEssentia Corporation

X
Drug Profile

Ropeginterferon alfa 2b - AOP Orphan Pharmaceuticals/PharmaEssentia Corporation

Alternative Names: A20-202; AOP-2014; BESREMi; Besremi; mono-pegylated interferon - PharmaEssentia Corporation; P-1101; Peg-IFN-alpha-2b; PEG-P-IFN-alpha-2b; Pegylated proline interferon-alfa-2b; Ropeg; Ropeginterferon alfa-2b-njft; Ropeginterferonum alfa 2b - AOP Orphan Pharmaceuticals/PharmaEssentia

Latest Information Update: 29 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmaEssentia Corporation
  • Developer AOP Orphan Pharmaceuticals AG; Institute of Liver and Biliary Sciences; Mayo Clinic; National Cancer Institute (USA); PharmaEssentia Corporation
  • Class Antihaemorrhagics; Antineoplastics; Antivirals; Interferons; Recombinant proteins
  • Mechanism of Action Interferon alpha-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Polycythaemia vera
  • Phase III Chronic myeloid leukaemia; Essential thrombocythaemia; Hepatitis B; Hepatitis C
  • Phase II Myelofibrosis
  • Phase I/II Liver cancer
  • Phase I Hepatitis D

Most Recent Events

  • 14 Sep 2023 PharmaEssentia initiates a phase III trial for Polycythemia vera in Japan (SC) (NCT06002490)
  • 21 Aug 2023 PharmaEssentia initiates a phase III trial in Polycythemia vera in Japan (SC) (NCT06002490)
  • 30 Jun 2023 Efficacy and adverse events data from phase II trial in Polycythemia Vera released by PharmaEssentia Corporation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top